Overview of China's Market Approval Policy Med Insurance Payment System

Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.

In this whitepaper, hear from Parexel rare disease consultants on the following topics:

  • Relevant Policies on Expedited Approval of Rare Disease Drugs 
  • An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs

Open PDF

Return to Insights Center

Related Insights


Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023


Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024


China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022


New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023


Enabling Successful Sites, Ep3: Taking the complexity out of oncology clinical trials

Jun 28, 2024


U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022


The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023


Reimbursement framework for medical devices in India

Mar 7, 2023


Insights from the 2022 R&D Innovation Survey

Feb 17, 2023


Are you using real-world evidence?

Feb 1, 2023


Innovative modeling method could speed patient access to critical IO therapies

Jan 4, 2023


Preparing for a new era in European Market Access

Jul 22, 2022